Mapping genetic factors and recurrence risk in East Asian breast cancer patients
The Cancer Genome Atlas and Recurrence Risk Prediction of East Asian Breast Cancer: a Multicenter Collaborative Study
This study is trying to find out how certain genes affect breast cancer and the chances of it coming back in East Asian patients to help improve treatment and predictions for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04344496 on ClinicalTrials.gov |
What this trial studies
This project aims to create a cancer genome atlas and a recurrence risk prediction platform specifically for East Asian breast cancer patients. It will collect blood samples, fresh tumor tissue, and paraffin-embedded tumor tissue from 2000 participants to identify unique genetic alterations in Asian tumors. The study seeks to pinpoint susceptible genes for breast cancer development in East Asia and establish a new method for accurately predicting recurrence. Additionally, it will explore the relationship between patient outcomes and genetic alterations found in the cancer atlas.
Who should consider this trial
Good fit: Ideal candidates include individuals over 20 years old with histologically confirmed invasive breast cancer and a tumor size of at least 1 cm.
Not a fit: Patients with ductal carcinoma in situ (DCIS) or those who have received neoadjuvant treatments or have metastatic breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for East Asian breast cancer patients.
How similar studies have performed: While this approach is focused on a specific population, similar studies have shown success in identifying genetic factors related to breast cancer, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged more than 20-year-old at the time of informed consent. * 2\. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer. * 3\. Have radiological or objective evidence of breast tumor size ≥1 cm. * 4\. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue. * 5\. Be able to sign an informed consent. Exclusion Criteria: * 1\. Have histologically confirmed ductal carcinoma in situ (DCIS). * 2\. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy. * 3\. Stage IV or metastatic breast cancer patients who have received chemotherapy.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Yen-Shen Lu, MD, PhD — National Taiwan University Hospital
- Study coordinator: Yen-Shen Lu, MD, PhD
- Email: yslu@ntu.edu.tw
- Phone: +886-223123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.